Anebulo Pharmaceuticals, Inc. (ANEB)
NASDAQ: ANEB · Real-Time Price · USD
0.4810
+0.0020 (0.42%)
Feb 17, 2026, 4:00 PM EST - Market closed
Anebulo Pharmaceuticals Employees
As of June 30, 2025, Anebulo Pharmaceuticals had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,659,583
Market Cap
19.62M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 3 | 0 | - | 2 | 1 |
| Jun 30, 2024 | 3 | 1 | 50.00% | 2 | 1 |
| Jun 30, 2023 | 2 | -2 | -50.00% | 2 | 0 |
| Jun 30, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Jun 30, 2021 | 3 | - | - | 2 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| Vistagen Therapeutics | 59 |
| Senti Biosciences | 34 |
| IN8bio | 17 |
| Serina Therapeutics | 13 |
| VYNE Therapeutics | 13 |
| Genenta Science | 13 |
| Neuphoria Therapeutics | 8 |
ANEB News
- 5 days ago - Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates - Business Wire
- 11 days ago - Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC - Business Wire
- 19 days ago - Anebulo Pharmaceuticals Announces Final Results of Tender Offer - Business Wire
- 21 days ago - Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer - Business Wire
- 2 months ago - Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer - Business Wire
- 3 months ago - Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates - Business Wire
- 5 months ago - Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates - Business Wire
- 5 months ago - Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity - Business Wire